We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COMPARISON OF ROSUVASTATIN AND ATORVASTATIN FOR LIPID LOWERING AND SAFETY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
- Authors
Nakova, Valentina Velkoska
- Abstract
Introdution. Dyslipidemia is associated condition of type 2 diabetes. Statins are first line therapy for dyslipidemia. They can cause elevations in liver biochemistries and there is a concern that patients with underlying liver disease may be at increased risk for hepatotoxicity. The aim of the study was to compare rosuvastatin with atorvastatin in reducing of lipids and their effect on hepatic enzymes. Material and methods. Prospective study on internal department in Clinical Hospital, Shtip, R of North Macedonia was performed. All patients with type 2 diabetes and dyslipidemia, who had been consecutive exanimated from January to April, 2019 year, without previously treatment with statins, were enrolled in the study. The choice of drug (rosuvastatin or atorvastatin) was random. The dose of statins were chosen depending of atherosclerotic cardiovascular disease (ASCVD) score. Fasting lipids, hepatic transaminases, creatinin phosphokinase, fasting glycaemia, and glycosylated hemoglobin (HbA1c), at baseline and after 2 months treatment with rosuvastatin or atorvastatin, were measured. Data were analyzed by SPSS statistical software using t-test for dependent samples. Results. Twelve (20%) man and 48 (60%) women, with mean age of 66 years, and mean body mass index=27kg/m2 finalised the study. Forty two patients (70%) received rosuvavstain, and 18 (30%) received atorvastatin. The two groups were well matched according the age and BMI. The average used doses of rosuvastatin and atorvastatin were 15.35 ± 4.98, and 22.0 ± 12.24mg, respectively. Both statins significantly reduced total cholesterol, LDL-C, and triglicerides. HDL-C level was increased, but without statistical significance. Rosuvastatin reduced total cholesterol and LDL-C levels more than atorvastatin. Atorvastatin reduced triglyceride levels more than rosuvastatin. Both of the statins didn’t changed hepatic transaminase and creatinin phosphokinase levels during treatment. The mean values of hepatic transaminases were even lower after treatment. Fasting glycaemia and HbA1c decreased without statistical significance after treatment. Both treatments were similarly well tolerated with no unexpected safety concerns. Conclusion. Statins are potent and safe drugs for dyslipidemia in patients with diabetes, and they have no adverse effect on liver function. According to our results rosuvastatin should be preferred statin when LDL-C is with higher values, and atorvastatin should be preferred when in addition to LDL-C, triglyceride should also be reduced.
- Subjects
ROSUVASTATIN; ATORVASTATIN; LIPIDS; TYPE 2 diabetes; HEPATIC artery
- Publication
Knowledge: International Journal, 2019, Vol 35, Issue 4, p1227
- ISSN
2545-4439
- Publication type
Article